

By: Senator(s) McMahan (By Request)

To: Public Health and
Welfare

SENATE BILL NO. 2757

1 AN ACT TO CREATE A TASK FORCE TO CONDUCT A STUDY OF THE
2 IMPACT OF ALTERNATIVE FUNDING PROGRAMS ON PATIENT ACCESS TO
3 AFFORDABLE PRESCRIPTION DRUGS; TO PROVIDE THAT THE MEMBERS OF THE
4 TASK FORCE SHALL BE COMPRISED OF THE MEMBERS OF THE MISSISSIPPI
5 RARE DISEASE ADVISORY COUNCIL OR THEIR DESIGNEES; TO PROVIDE THAT
6 THE FIRST MEETING OF THE TASK FORCE SHALL BE HELD BY MAY 15, 2025;
7 TO SPECIFY THE SUBJECTS AND ISSUES THAT THE STUDY SHALL CONSIDER;
8 TO PROVIDE THAT THE TASK FORCE SHALL COMPLETE THE STUDY NOT LATER
9 THAN DECEMBER 1, 2025, AND TRANSMIT COPIES OF THE STUDY TO CERTAIN
10 PERSONS, AND PROVIDE A WRITTEN REPORT OF ITS FINDINGS FROM THE
11 STUDY, TOGETHER WITH ANY RECOMMENDATIONS FOR LEGISLATION, TO
12 CERTAIN OFFICIALS AND LEGISLATIVE COMMITTEES; AND FOR RELATED
13 PURPOSES.

14 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

15 SECTION 1. (1) There is created a task force to conduct a
16 study of the impact of alternative funding programs on patient
17 access to affordable prescription drugs, for the purpose of
18 ensuring access to medically necessary medication for patients in
19 Mississippi. The members of the task force shall be comprised of
20 the members of the Mississippi Rare Disease Advisory Council
21 established by Section 41-145-3, and any member of the council may
22 appoint a designee who shall serve on the task force on his or her
23 behalf.



24 (2) The member of the council who is a physician with
25 experience treating rare diseases who is practicing in the state
26 shall serve as the chairman of the task force, and the staff of
27 the council shall provide support to the task force.

32 (4) The names of any persons who are designated by council
33 members as provided in subsection (1) of this section shall be
34 submitted to the chairman of the task force within thirty (30)
35 days after the effective date of this act. The chairman shall
36 call the first meeting of the task force by May 15, 2025.

41 (6) The task force shall conduct a study on the impact of
42 alternative funding programs on patient access to affordable
43 prescription drugs, which shall include a study of the following:

44 (a) The history and prevalence of alternative funding
45 programs in the United States and Mississippi, including, but not
46 limited to, the types of health insurance products that use, in
47 whole or in part, alternative funding programs to provide access,
48 coverage or discounts for prescription drugs;

49 (b) The business model of alternative funding programs;
50 (c) The impact of alternative funding programs on
51 patient assistance programs for prescription medications,
52 including, but not limited to, long-term stability of those
53 patient assistance programs if an upswing in alternative funding
54 programs is realized across an increased number of health
55 insurance products; and

56 (d) The impact of alternative funding programs on
57 coverage of prescription medications if the use of alternative
58 funding programs is expanded across additional insurance products,
59 including, but not limited to, commercial health coverage plans,
60 health coverage plans offered to public employees, and health
61 coverage plans offered to individuals in the state's health
62 insurance exchange.



81 (8) The task force shall terminate upon the date of
82 submission of its study.

83 **SECTION 2.** This act shall take effect and be in force from
84 and after its passage.

